Official Title
A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit
Brief Summary

The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to the ICU through Day 29.

Completed
COVID-19

Biological: GAMUNEX-C

Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.
Other Name: IGIV-C

Drug: Standard Medical Treatment

SMT per local policies or guidelines.

Eligibility Criteria

Inclusion Criteria:

- Hospitalized male or female subjects of ≥ 18 years of age at time of Screening who are
being treated in the ICU for COVID-19 for not longer than 48 hours or for whom a
decision has been made that COVID-19 disease severity warrants ICU admission.

- Has laboratory-confirmed novel coronavirus {SARS-CoV-2} infection as determined by
qualitative polymerase chain reaction (PCR) (reverse transcriptase [RT]-PCR), or other
United States Food and Drug Administration (FDA)-approved diagnostic assay for
COVID-19 in any specimen during the current hospital admission prior to randomization.

- Illness (symptoms of COVID-19 of any duration requiring ICU level care), and the
following:

1. Radiographic infiltrates by imaging (chest X-Ray, computerized tomography (CT)
scan, etc.), and

2. Requiring mechanical ventilation and/or supplemental oxygen.

- Any one of the following related to COVID-19: i. Ferritin > 400 nanogram per
milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) > 300 units per liter (U/L), iii.
D-Dimers > reference range, or iv. C-reactive protein (CRP) > 40 milligram per liter
(mg/L).

- Subject provides informed consent prior to initiation of any study procedures.

Exclusion Criteria:

- Clinical evidence of any significant acute or chronic disease or pathophysiologic
manifestations (eg, complications of COVID-19 standard medical treatments) that, in
the opinion of the investigator, may place the subject at undue medical risk.

- The subject has had a known (documented) serious anaphylactic reaction to blood, any
blood-derived or plasma product or a past history of any hypersensitivity reactions to
commercial immunoglobulin.

- A medical condition in which the infusion of additional fluid is contraindicated.

- Shock that is unresponsive to fluid challenge and/or multiple vasopressors and
accompanied by multiorgan failure considered by the Principal Investigator not able to
be reversed.

- Subjects with known (documented) thrombotic complications to polyclonal IVIG therapy
in the past.

- Subjects with current or prior myocardial infarction, stroke, deep vein thrombosis, or
thromboembolic event (within the past 12 months) or who have a history of
thromboembolic events of unknown etiology.

- Subjects with limitations of therapeutic effort.

- Female subjects who are pregnant or of child-bearing potential with a positive test
for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at
Screening/Baseline.

- Subjects participating in another interventional clinical trial with investigational
medical product or device.

- Known history of prothrombin gene mutation 20210, homozygous Factor V Leiden
mutations, antithrombin III deficiency, protein C deficiency, protein S deficiency or
antiphospholipid syndrome.

- Presence of malignancy (either new diagnosis of malignancy or known residual disease)
within the past 12 months.

- Creatinine at Screening is ≥ 4 mg/dL (or subject is dependent on dialysis/renal
replacement therapy).

- Known Immunoglobulin A (IgA) deficiency with anti-IgA serum antibodies.

- Uncontrolled hypertension at the time of Screening (systolic blood pressure > 200 mm
Hg) or refractory severe hypotension with sustained systolic blood pressure < 90 mm Hg
unresponsive to vasopressors.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Chandler Regional Medical Center
Chandler, Arizona, United States

Southern California Research Center
Coronado, California, United States

University of Illinois at Chicago
Chicago, Illinois, United States

Via Christi Research
Wichita, Kansas, United States

University of Louisville
Louisville, Kentucky, United States

Louisiana State University Health Sciences Center
Shreveport, Louisiana, United States

McLaren Flint
Flint, Michigan, United States

McLaren Health Care-Macomb
Mount Clemens, Michigan, United States

McLaren Health Care Oakland
Pontiac, Michigan, United States

CHI Health
Omaha, Nebraska, United States

Columbia University Medical Center
New York, New York, United States

Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States

Summa Health
Akron, Ohio, United States

Temple University Hospital
Philadelphia, Pennsylvania, United States

Allegheny Health Network Research Institute
Pittsburgh, Pennsylvania, United States

CHRISTUS Health
Tyler, Texas, United States

MultiCare Deaconess Hospital
Spokane, Washington, United States

MultiCare Tacoma General Hospital
Tacoma, Washington, United States

Simon Mahler, MD, Principal Investigator
Wake Forest Baptist Medical Center

Grifols Therapeutics LLC
NCT Number
Keywords
coronavirus disease
Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
Coronavirus Infections
Coronaviridae Infections
Virus Diseases
Immunoglobulins
Antibodies
Gamma-globulins
Immunoglobulins, Intravenous
Immunologic Factors
Physiological Effects of Drugs
MeSH Terms
COVID-19
Immunoglobulins, Intravenous